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TREATMENT AND PLACEBO EFFECTS IN BLINDED
AND UNBLINDED RANDOMIZED CLINICAL TRIALS
INFLUENCED BY UNMEASURED CONFOUNDERS
By Elias Chaibub Neto
Sage Bionetworks
Clinical trials traditionally employ blinding as a design mech-
anism to reduce the influence of placebo effects. In practice, how-
ever, it can be difficult or impossible to blind study participants
and unblinded trials are common in medical research. Here we show
how instrumental variables can be used to quantify and disentangle
treatment and placebo effects in randomized clinical trials compar-
ing control and active treatments in the presence of confounders.
The key idea is to use randomization to separately manipulate treat-
ment assignment and psychological encouragement messages that in-
crease the participants’ desire for improved symptoms. The proposed
approach is able to improve the estimation of treatment effects in
blinded studies and, most importantly, opens the doors to account
for placebo effects in unblinded trials.
1. Introduction. Placebo effects have draw a lot of interest and de-
bate in medicine[1]. They can be viewed as a simulation of an active therapy
within a psychosocial context[1]. Research in neurobiology has shown that
placebo responses are accompanied by actual alterations in neural activ-
ity within brain regions involved in emotional regulation[1, 2, 3, 4]. Hence,
rather than inducing a simple bias in response, placebos can induce actual
biological effects and improve clinical outcomes. Among the cognitive and
emotional factors that have been proposed to contribute to placebo effects,
the interaction between the desire for symptom change and the expected
symptom intensity has been proposed as a key component giving raise to
placebo effects[1]. In the psychology literature, this interaction is known as
the desire-expectation model of emotions[1, 5, 6, 7], which postulates that
ratings of positive and negative emotional feelings are predicted by multi-
plicative interactions between ratings of desire and expectation. A number
of experimental studies of placebo analgesia[1, 8, 9] have corroborated the
role of the desire-expectation model as a trigger of placebo effects. These
findings have important implications for both clinical practice and clini-
cal trials. On one hand, clinicians should harness the placebo effect to im-
prove the clinical outcome of their patients (by managing expectations and
desires through ethical use of suggestions and optimum caregiver-patient
1
2 CHAIBUB NETO E.
interactions)[1]. On the other hand, assessment of expectation and desire
levels is also important in clinical trials since placebo effects might strongly
influence the results of a study. In unblinded trials, it is widely recognized
that the overall effect attributed to a treatment might actually correspond
to a combination of treatment and placebo effects. However, placebo effects
might still play a role in blinded trials as well[1]. For instance, blinded stud-
ies evaluating the effectiveness of acupuncture[10] and of implantation of
human embryonic dopamine neurons into the brains of persons with severe
Parkinson disease[11] have shown that perceived treatment (or the treat-
ment the participants thought they had received) can have stronger effects
than the treatment actually received by the participants. These findings il-
lustrate the relevance of measuring expectation, desire, and emotional levels
in order to assess the contribution of placebo effects, and suggest that it is
important to adjust for these variables when estimating treatment effects
and interpreting the results of clinical trials[1]. However, because it is gener-
ally impossible to rule out the presence of unmeasured confounders, simply
measuring and adjusting for variables associated with placebo effects might
not be enough to ensure a reliable estimation of the treatment effect. For
instance, estimation based on regression models adjusting for the placebo
related measurements still leads to biased estimates of the treatment effect,
unless all confounders influencing the outcome variable enter the regression
model.
2. The statistical method. Here we present a statistical approach to
disentangle treatment and placebo effects using instrumental variables[12,
13, 14] in randomized experiments. An instrumental variable (IV) is statisti-
cally independent from any unmeasured confounders, but is associated with
the treatment variable and with the outcome variable (via its influence on
the treatment variable alone). Use of IVs in randomized experiments allows
the consistent estimation of treatment effects without the need to explicitly
model the confounders (the technique even accounts for confounders the
researcher is unaware about).
Our proposed method requires the ability to assess variables associated
with placebo effects (e.g., levels of expectancy, desire, and emotion), and
uses randomization to separately manipulate a pair of variables. The first,
corresponds to a psychological encouragement variable aiming to increase
the desire for improved symptoms. The study participants are randomized
according to whether they receive the psychological encouragement or not.
This “psychological treatment” IV allows the consistent estimation of the
placebo effect on the outcome in the presence of confounders. The second,
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corresponds to a treatment assignment variable representing the random as-
signment of participants to active treatment or control therapy groups. It
allows the estimation of the treatment effect on the outcome, after adjust-
ment for the placebo effect. Mechanistically, the approach corresponds to
a two-step procedure, which first estimates the contribution of the placebo
effect on the outcome, and then the effect of the treatment on the residuals
of the outcome variable after the contribution of the placebo effect has been
removed.
A graphical representation of the causal model underlying our approach
is given in Figure 1a. Circled and un-circled nodes represent observed and
unobserved variables, respectively. Arrows represent the causal influence of a
variable on another, with the influence of unmeasured confounders shown as
dotted arrows. The binary variable Z represents the randomized treatment
assigned to the participant (1 if participant is assigned to the active treat-
ment group, and 0 if assigned to the control group), while X represents the
treatment actually received by the study participant (1 if the participant re-
ceives the active treatment, and 0 otherwise). It is important to model both
assigned and received treatment variables since participants won’t necessar-
ily subscribe to their assigned treatment, and the experiment might suffer
from imperfect compliance.
The variable S represents the unmeasured biochemical/physiological (so-
matic) state of a participant and mediates the effect of the treatment on the
outcome variable, Y . For instance, if X represents a drug treatment, then S
could represent the physiological state induced by the biochemical pathways
targeted by the drug. The causal effects of X on S and of S on Y are quanti-
fied, respectively, by η and λ. The outcome variable is also influenced by the
unmeasured psychosomatic state of the participant, represented by P . We
allow P to influence Y via a direct path, quantified by τ , and by an indirect
path, mediated by S, and quantified by the product δ λ. The combined effect
of the direct and indirect paths represents the placebo effect. The direct path
from P to Y represents the influence of the psychosomatic state on the out-
come mediated by biochemical and physiological pathways distinct from the
pathways influenced by the active treatment, while the influence of P on S
allows for the possibility that P also influences the same pathways targeted
by the treatment X. (Experimental evidence that placebo effects influence
biochemical pathways is provided, for example, in studies of placebo anal-
gesia involving endogenous opioid systems[1, 15, 16, 17, 18, 19, 20]. See also
figure 2 in reference[21], for empirical support about pathways influenced by
both psychosocial context and drug treatments.)
The role played by the expectation-desire model of emotions is made
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Fig 1. Direct acyclic graph representation of the causal model underlying the proposed
IV approach for disentangling treatment and placebo effects in unblinded clinical trials.
Circled and un-circled nodes represent observed and unobserved variables, respectively.
Arrows represent the causal influence of a variable on another, with the influence of con-
founders on variables shown as dotted arrows. The Z and X nodes represent, respectively,
the participant’s assigned and received treatment, whereas Q stands for the psychological
encouragement treatment. The S and P variables represent the (unobserved) somatic and
psychosomatic states of the participant, respectively. The E, D, I, and M nodes stand for
the participant’s expectation of symptom intensity, desire for improved symptoms, desire-
expectation interaction, and emotional level, respectively. The sets of variables U , C1, C2,
C3, L1, L2, L3, V 1, V 2, V 3, and H stand for unmeasured confounder variables. The
Y node represents the outcome variable. Panel a shows the full model. Panel b shows the
reduced model where the unobserved somatic and psychosomatic states of a participant are
not directly represented in the causal model.
explicit by the observed variables E, D, I and M , representing, respec-
tively, the expected symptom intensity, the desire for symptom improve-
ment, the interaction between expectation and desire, and the emotional
level (measured, for example, by the participant’s mood). According to the
expectation-desire model, M is directly influenced by E, D, and their inter-
action I = E ×D. The causal influence of M on P is quantified by φ.
In unblinded trials it is reasonable to expect that the treatment actually
received by the participant will affect its expected symptom intensity, since
participants who know they are receiving the active treatment will more
likely experience an increase in their expectation to feel better. Hence, we
include an arrow from X to E. The implication is that the treatment can
influence the outcome not only via the participant’s somatic state, but also
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by its psychosomatic state via the paths X → E →M → P and X → E →
I →M → P . The binary variable Q represents the randomized psychological
encouragement IV assuming the value 1 when a encouragement message
(aiming to increase the desire for symptom improvement) is applied to the
participant, and 0 otherwise.
In addition to the key variables described so far, it is important to rec-
ognize the existence of unmeasured confounders. Except for the exogenous
variables Z and Q, that by construction are not associated with any unmea-
sured confounders, the model includes confounders influencing all pairs of
endogenous variables other than I, namely, X, E, D,M , P , S, and Y . (It is
not necessary to include confounders between I and the other endogenous
variables, since I is deterministically computed as the product of E and
D). For instance, U represents a set of unmeasured confounder variables
influencing X and Y . In order to avoid cluttering the figure, the confounder
variables influencing S and P and all other endogenous variables are rep-
resented by the vector of variables H = (H1, . . . ,H11)
T . (For the same
reason the figure does not explicitly shows the error terms, which account
for unmeasured variables influencing each particular variable in the model
and are uncorrelated with each other). It would be unrealistic to assume,
for example, that the emotion of a participant is determined by E, D, and
I alone. Hence, the model allows sets of unmeasured confounders, such as
L1, L2 and L3, to influence emotion and expectation, emotion and desire,
and expectation and desire, respectively. Similarly, it would be unrealistic
to assume that emotion alone influences the psychosomatic state of a par-
ticipant, and the model accommodates unmeasured confounders influencing
these variables as well. Although, in practice, not all endogenous variables
(other than I) will necessarily be influenced by confounders, the model still
includes confounders for all 21 pairwise combinations of endogenous vari-
ables, since we want to derive estimators for the placebo and treatment
effects under the most general setting possible.
In practice, however, it is impossible to accurately measure the unobserved
somatic and psychosomatic states of a participant. Hence, Figure 1b presents
a reduced version where S and P are not explicitly represented in the graph.
Assuming linear relationships between S and X, P andM , and Y , S, and P ,
the causal influence of X on Y is given by β = η λ, while the influence of M
on Y is given by ψ = φ τ +φ δ λ. Under this reduced model the instrumental
variable Q allows for the consistent estimation of the net placebo effect, ψ,
using the IV estimator ψ̂ = Ĉov(Q,Y )/Ĉov(Q,M). Once the net placebo
effect is estimated, it is possible to estimate the causal effect of X on Y using
the IV estimator of the causal effect of X on the residuals of the outcome
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variable after the removal of the placebo effect, β̂ = Ĉov(Z, R̂)/Ĉov(Z,X),
where R̂ = Y − ψˆ M (see Methods for details).
3. Performance evaluation. We assessed the statistical performance
of the proposed method (and compare it to a naive regression approach)
in 16 simulation experiments evaluating the empirical type I error rate and
empirical power of randomization tests for the null hypotheses that the
placebo effect is zero, H0 : ψ = 0, and that the treatment effect is zero, H0 :
β = 0. Descriptions of the randomization tests and simulation experiments
are provided in the Methods. We simulated data from blinded and unblinded
trials, in the presence and absence of confounders, according to the models
presented in Figure 2.
For each setting, we ran 4 separate simulation experiments generating
data: (i) under the null for treatment and placebo effects; (ii) under the alter-
native for treatment, and null for placebo effects; (iii) the other way around;
and (iv) under the alternative for treatment and placebo effects. Each simu-
lation experiment employed 10,000 distinct synthetic data sets with diverse
characteristics (see Methods). Although the randomization tests are non-
parametric procedures free of distributional assumptions, we still generated
data using gaussian errors in order to met the distributional requirements
of the regression based analytical tests used in our comparisons.
Figure 3 presents the results for the placebo effect tests, and shows that
the error rates of the IV approach (red and blue) are controlled at the exact
nominal levels in both blinded and unblinded settings, in the presence and
absence of confounders. The regression approach (brown and dark-orange),
on the other hand, shows highly inflated errors in the presence of confounders
(panels a and b), since the association between M and Y , caused by con-
founders, is mistaken by an influence of M on Y . Being able to control type
I error rates at the exact nominal level is a desirable statistical property, as
it means that the test is neither conservative nor liberal.
Figure 4 presents the results for the treatment effect tests in the blinded
setting. In addition to the two-step estimator (blue), we also evaluated the
simple IV estimator β̂ = Ĉov(Z, Y )/Ĉov(Z,X), which does not account for
the placebo effect (red). The results show, again, well controlled error rates
for both IV approaches, but inflated errors for the regression test (brown)
in the presence of confounders (panels a and b).
Figure 5 presents the results for the unblinded case. All panels show
slightly inflated errors for the two-step IV estimator (blue). The likely rea-
son is that the estimated placebo effects are noisy and unable to completely
block the influence of X on Y through the paths mediated by M . To test
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Fig 2. Models used in the simulation study. Panels a and b represent, respectively, blinded
and unblinded trials influenced by confounders. For simplicity we include a single con-
founder variable per pair of endogenous variables (other than I), but still simulate con-
founding across the 10 possible pairwise combinations of the endogenous variables X, Y ,
E, M , and D. Panels c and d represent, respectively, unconfounded blinded and unblinded
trials. For simulations under the null H0 : ψ = 0 there are no arrows from M to Y .
Similarly, for simulations under H0 : β = 0, there are no arrows from X to Y .
this supposition, we evaluated an additional IV estimator, where the true
placebo effect was used in the computation of the residuals (i.e., we esti-
mated β by β̂ = Ĉov(Z,R)/Ĉov(Z,X), where R = Y − ψM , instead of
β̂ = Ĉov(Z, R̂)/Ĉov(Z,X), where R̂ = Y − ψˆ M). Results based on this
estimator (dark-orange) show that, indeed, adjustment by the true placebo
effect leads to error rates controlled at the nominal level. The regression
approach (brown) shows again highly inflated errors in the presence of con-
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Fig 3. Empirical type I error rates of the placebo effect null, H0 : ψ = 0, in both blinded
and unblinded settings. Panels a and b show that, in the presence of confounders, the type
I error rate of the IV approach is controlled at the exact nominal level (red and blue),
whereas the regression based test leads to highly inflated error rates (orange and brown).
Panels c and d show that, in the absence of confounding, both IV and regression approaches
show well controlled errors. The nominal significance level is represented by α.
founders (panels a and b). Panels a and c show well controlled errors for
the non-adjusted IV estimator (red) in the absence of placebo effects as, in
this case, there are no paths from X to Y , and the association between X
and Y induced by confounders is accounted by the IV estimator. Panels b
and d, on the other hand, show highly inflated error rates in the presence
of placebo effects since, in this case, X can influence Y through the paths
mediated by M .
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Fig 4. Empirical type I error rates for the treatment effect null, H0 : β = 0, in the blinded
setting. Panels a and b show that, in the presence of confounders, the type I error rates
of the IV approaches are controlled at the exact nominal level (red and blue), whereas the
regression based test leads to highly inflated error rates (brown). Panels c and d show that,
in the absence of confounding, both IV and regression approaches show well controlled
errors. The nominal significance level is represented by α.
These observations suggest that, in practice, when analyzing the results
of unblinded trials, we should first test for the existence of placebo effect,
and then use the two-step IV estimator if H0 : ψ = 0 is rejected, and the
non-adjusted one if H0 : ψ = 0 is accepted. While this strategy can decrease
the chance of the two-step approach making a type I error in the absence of
placebo effects, the estimator is still unable to avoid slightly inflated errors
produced in the presence of placebo effects. We point out, however, that the
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Fig 5. Empirical type I error rates for the treatment effect null, H0 : β = 0, in the
unblinded setting. The two-step IV approach (blue) shows slightly inflated errors in the
presence (panels a and b) and absence (panels c and d) of confounders. Note that the
larger errors in panels c and d, in comparison to a and b, are likely due to the effective
stronger influence of X on M in the simulations unaffected by confounders (the presence
of confounders can considerably increase the amount of noise), so that adjustment by
ψˆ leaks more information about X in the absence than in the presence of confounders.
The estimator adjusted by the true placebo effect (dark-orange) leads, nonetheless, to well
controlled errors. The non-adjusted IV approach (red) leads to well controlled errors in the
absence of placebo effects (panels a and c), but to highly inflated errors in the presence of
placebo effects (panels b and d). Regression (brown) leads to highly inflated errors in the
presence of confounders (panels a and b), but to well controlled error rates in their absence
(panels c and d).
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two-step procedure still represents a strong improvement over the alternative
approach of not adjusting for placebo effects in the presence of confounders
(compare the red and blue curves in panel b of Figure 5).
For completeness, we also report an evaluation of the empirical power
(Figures 6, 7, and 8). We point out, however, that power results are more
sensitive to the choice of parameter values employed in the generation of
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Fig 6. Empirical power to detect placebo effects in the blinded and unblinded settings.
Panels a and b show the results in the presence of confounders, whereas panels c and
d show the results in their absence. The regression approach (brown and dark-orange)
were considerably better powered than the IV approaches (blue and red) in the presence of
confounders (panels a and b), but only slightly better powered in the absence of confounders
(panels c and d). Both regression and IV approaches showed similar power under the
blinded and unblinded settings.
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Fig 7. Empirical power for detecting treatment effects in the blinded setting. The regression
approach (brown) tends to be better powered than the IV approaches in the presence of
confounders (panels a and b), but only slightly better in the absence of confounding (panels
c and d). The two-step IV approach (blue) tends to be better powered than the non-adjusted
one (red) in the presence of placebo effects (panels b and d), but both IV approaches tend
to be comparable in absence of placebo effects (panels a and c).
the simulated data (e.g., sample size, the strength of treatment, placebo
and confounding effects, and etc), than the type I error rates. In any case,
these empirical power results, still serve to illustrate some general patterns.
For instance, the regression tests tended to show considerably stronger power
than the IV approaches in the presence of confounders (compare the brown
and blue curves in panels a and b of Figures 7 and 8). We point out, however,
that this increased power is likely an artifact of the biased estimates of β
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Fig 8. Empirical power for detecting treatment effects in the unblinded setting. The regres-
sion approach (brown) tended to be better powered than the IV approaches in the presence
of confounders (panels a and b), but comparable in the absence of confounding (panels
c and d). The two-step IV approach (blue) tended to be slightly better powered than the
non-adjusted one (red) in the presence of placebo effect (panel b), but comparable in the
other panels.
outputted by the regression approach. Figure 9, illustrates how the regression
estimates tended to show larger bias than the estimates generated by the IV
estimators (note the heavier tails of the brown density, in both blinded and
unblinded cases). In other words, the increased power is likely a consequence
of the overestimation of the treatment effect by the regression approach,
which mistakenly interprets the association between treatment and outcome
caused by unmeasured confounders as a stronger influence of the treatment
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on the outcome.
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Fig 9. Comparison of the bias of the regression and IV estimators. Panels a and b show
the densities of the difference between true and estimated treatment effects, β − βˆ, in the
blinded and unblinded settings, respectively. In both settings we observed larger bias in the
regression estimates, in comparison to the IV approaches, as illustrated by the heavier tails
of the brown densities.
At least for the parameter ranges adopted in our simulations, we observed
good empirical power of the IV approach to detect placebo effects, even
when the correlation between psychological encouragement and emotional
level was relatively low (Figure 10a). This suggests that the psychological en-
couragement treatment does not need to be highly effective in manipulating
the emotional levels, in order for the approach to work well in practice. Sim-
ilarly, Figure 10b shows good empirical power of the two-step IV approach
to detect treatment effects when the correlation between the assigned and
received treatment is moderate, suggesting that the proposed approach does
not require high levels of compliance in order to perform well.
A natural question, at this point, is whether larger sample sizes (and,
hence, more precise estimates of ψˆ) would be able to decrease the slightly
inflated error rates produced by the two-step estimator in unblinded trials.
Figure 11 presents additional simulation experiments showing that, while the
empirical power and the ψˆ and βˆ estimates are greatly improved by larger
sample sizes, the type I error rates stay roughly the same (likely because
larger sample sizes increase the ability of a test to detect small effects, since
the randomization null distributions tend to be more concentrated around
0, so that the improved ψˆ estimates are counterbalanced by the increased
propensity to detect small and spurious treatment effects). These results
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Fig 10. Empirical power curves stratified by strength of association with the IV variable.
Panel a shows the power curves for the placebo effect IV estimator ψˆ, stratified according
to the correlation between Q and M (panel c shows the distribution of the correlation
between Q and M across all simulations used to construct the power curves in panel
a). Panel b shows the power curves for the two-step treatment effect IV estimator βˆ,
stratified according to the correlation between Z and X (panel d shows the distribution of
the correlation between Z and X over the simulations used to estimate the power curves
in panel b). Results based on blinded and unblinded simulations influence by confounders.
suggest that special care must be taken while interpreting the results of
hypothesis tests in the unblinded case, even for large sample sizes. In any
case, when the goal is estimation rather than testing, the consistency of the
two-step estimator guarantees that the treatment estimates will converge to
the true value as the sample size increases.
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Fig 11. Consistency of the ψˆ and βˆ estimators. Panels a and b present, respectively,
the densities of ψ − ψˆ and β − βˆ for 5 increasing sample size ranges, and illustrate the
consistency of the ψˆ and βˆ estimators (which tend to get closer to the true parameter
values as the sample size increases). Panel c shows that, as expected, the statistical power
to detect a treatment effect increases with the sample size. Panel d, on the other hand,
shows that increasing sample sizes do not reduce type I error rates, even though we are
able to better estimate the placebo effects. The likely reason is that while larger sample
sizes lead to better ψˆ estimates, they also increase the statistical power to detect very
small effects, so that the advantage of a more precise estimate of ψˆ is counterbalanced
by the increased propensity to detect small and spurious treatment effects as true signals.
Results were based on data simulated from unblinded trials influenced by placebo effects
and counfounders, as described in the Methods section.
This observation is particularly important in view of the current trend in
the biomedical field, where researchers are shifting from relying exclusively
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in p-values and are paying more attention to parameter estimates and con-
fidence intervals. To meet this latter need, we also describe in the Methods
how to generate confidence intervals (CIs) for placebo and treatment effects
by inverting randomization tests. Figure 12 shows 95% CIs for the placebo
and treatment effects, from 3 simulated data sets of increasing sizes. The
randomization CIs inherit the statistical properties of the randomization
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Fig 12. Randomization confidence intervals for placebo and treatment effects. The brown,
dark-green and blue curves show the one-sided p-value profiles derived from randomiza-
tion tests for 3 simulated data sets of increasing sizes (300, 900, and 2,700, respectively),
generated under the unblinded setting influenced by confounders (all simulation parame-
ters, other than sample size, were set to 1). The 95% confidence intervals for the placebo
(panel a) and treatment effects (panel b) are shown by the respective double-headed colored
arrows. The red vertical line corresponds to the true parameter values, ψ = 1 and β = 1.
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tests, hence, the placebo effect CIs (and treatment effect CIs from blinded
trials) are exact in the sense that a 100(1 − α)% interval will contain the
true parameter value 100(1 − α)% of the time. Note that while the treat-
ment effect CIs from unblinded trails won’t be exact, they are still going to
be centered around the estimated treatment effect, which will, nevertheless,
converge to the true value as the sample size increases.
4. Discussion. Clinical trials traditionally employ blinding to control
the influence of placebo effects. It has being pointed out, however, that even
blinded studies might be influenced by placebo effects, as the patients per-
ceptions and beliefs about the treatment they think they received are able to
trigger strong placebo effects[1, 11, 10]. Recently, a number of statistical ap-
proaches have been proposed to quantify the contributions of treatment and
placebo effects to a clinical outcome[22, 23, 24]. These approaches, nonethe-
less, are tailored to blinded trials, and leverage blinding assessment data
to quantify the amount of unmasking taking place during the trial. Our
IV approach, on the other hand, allows the quantification of treatment and
placebo effects not only in blinded, but also in unblinded trials.
The key idea underlying the IV approach (what actually allows the con-
sistent estimation of both treatment and placebo effects in the presence of
unmeasured confounders), is the use of randomization to separately manip-
ulate the treatment assignment and encouragement messages. In this sense,
the proposed approach is similar in spirit (but not exactly equivalent) to
a randomized treatment-belief trial (RTB)[25], where the treatment assign-
ment is manipulated by randomization, whereas the belief is manipulated
by varying the allocation ratio of participants assigned to control and treat-
ment groups in a, necessarily, blinded trial. Hence, our IV approach can be
viewed as a more flexible type of RTB that is applicable to both blinded
and unblinded studies, and might be easier to administer than a standard
RTB, which requires the stratification of study participants over several
arms with distinct treatment/control allocation ratios in order to be able to
assess placebo effects.
The proposed IV approach enjoys appealing statistical properties. The
IV estimators are consistent, meaning that the estimates converge to the
true values as sample size increases. The randomization tests for placebo
effects are exact in both blinded and unblinded trails, whereas the treatment
effect tests are exact in blinded trials, but slightly liberal in unblinded ones.
Furthermore, the confidence intervals obtained by inverting randomization
tests inherit these appealing properties.
An implicit assumption of the model in Figure 1a is that the placebo effect
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is mediated exclusively by the interplay of desire, expectation, and emotion.
While it is believed that the desire-expectation model plays a key role in the
triggering of placebo effects, other mechanisms, such as conditioning, might
also be at work[1, 21]. Clearly, when this is the case, a treatment effect
estimate, adjusted by the desire-expectation component alone, will still be
biased (although less biased than the estimate computed without accounting
for it). In any case, if we are also able to assess and measure these additional
mechanisms, then the same statistical framework can be used to obtain con-
sistent estimates of treatment effects in the presence of confounders (we only
need additional IVs to manipulate the additional placebo related variables).
Figure 13 shows an example.
From a pragmatic perspective, the proposed method is easy to implement.
It only requires the ability to assess expectation, desire, and emotion, as
well as, the development of a psychological encouragement IV, capable of
manipulating the level of desire of a study participant. For example, in trials
run into a clinic, a simple encouragement conversation with a caregiver would
work as the “active treatment” of the psychological encouragement IV. The
desire and emotional level could then be recorded by a questionnaire or
interview after the encouragement treatment, but prior to the measurement
of the outcome variable.
Another application of the proposed method (the one that actually mo-
tivated this work) is in the personalized monitoring of treatment response
in mobile health. The statistical validity of using treatment assignment as
an IV, in the context of longitudinal data provided by a single patient, has
been established in reference[26]. However, as pointed out by the authors,
it is impossible to disentangle treatment and placebo effects based on the
treatment assignment IV alone, since it is impossible to blind the patient
to a self administered treatment. Implementation of the proposed IV ap-
proach in mobile health applications is also strait-forward. For instance, the
psychological treatment could be delivered by encouragement messages pop-
ping up in the screen of a smartphone (according to a randomized schedule,
where every day the participant has an equal chance of receiving, or not, the
encouragement message), and the measurement of the emotional and desire
levels can be assessed by short electronic surveys/quentionnaires delivered
by the participant’s smartphone on a daily basis. We expect the proposed
method to play an important role in these personalized medicine[27, 28]
applications.
Finally, for both (population-based) clinical trials and personalized mon-
itoring of treatment response, the instrument Q serves the double role of
disentangling placebo from treatment effects, and increasing the desire for
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Fig 13. A more complex example. Panel a presents a more complex model where the placebo
effect is mediated by M (according to the desire-expectation model) but also by an addi-
tional variable A. Assuming that a randomized instrument, W , is available to manipulate
A, we can estimate the treatment effect using the estimator βˆ∗ = Ĉov(Z, Rˆ∗)/Ĉov(Z,X)
where Rˆ∗ = Y − ψˆ M − κˆ A. Panel b shows the empirical type I error rates for a simula-
tion experiment under the unblinded setting influenced by confounders. The IV estimator
adjusted by the true ψ and κ values is able to control error rates at the nominal levels (dark-
orange). The IV estimator adjusted by ψˆ and κˆ shows slightly inflated errors (dark-green).
As expected, adjustment with ψˆ alone (blue) leads to higher error rates than adjustment
with both ψˆ and κˆ. Similarly, the IV estimator using no adjustment (red) has higher errors
than adjustment by ψˆ alone. The regression based estimator (brown) is adjusted by both
M and A covariates, but still leads to inflated errors due to the presence of confounders.
Panel c shows the empirical power results.
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improved symptoms. This latter capacity can induce a placebo effect and
ultimately lead to more positive clinical outcomes. While the manipulation
of the expectation for symptom intensity could, in principle, be used to con-
sistently estimate a placebo effect under the proposed approach (i.e., we
could have an IV influencing E instead of D), the manipulation of expecta-
tion levels needs to be accompanied by the honest disclosure of the expected
benefits of a treatment (and, in some cases, might raise ethical issues)[21].
Manipulation of the desire for improved symptoms, on the other hand, pro-
vides an ethically defensible practice in the design of clinical trials and in
the personalized monitoring of patients.
5. Methods.
5.1. Identification of causal effects using instrumental variables. We sub-
scribe to the mechanism-based account of causation championed by Pearl[29].
In this framework, the qualitative description of the assumptions regarding
the causal relations between the variables involved in our proposed method,
is encoded by the directed acyclic graph presented in Figure 1a. Assuming
a linear relation between the outcome, Y , and the unobserved somatic and
psychosomatic state variables, S and P , we have that,
(1) Y = µY + λS + τ P + fY (U ,V ,H) + ǫY ,
where V = (V 1,V 2,V 3)
T , H = (H1, . . . ,H11)
T , ǫY represents an error
term accounting for the unmeasured variables influencing exclusively Y ,
and fY (U ,V ,H) represents is a general scalar function of the variables in
(U ,V ,H) influencing Y .
Since S and P are unobserved variables, we need to derive the reduced
model for the outcome variable that is not a function of S and P . Assuming
a linear relation between P and M , and between S and P and X, we have
that,
P = µP + φM + fP (H) + ǫP ,(2)
S = µS + η X + δ P + fS(H) + ǫS ,(3)
where fP (H) and fS(H) are arbitrary scalar functions of H, and ǫP and
ǫS are the respective error terms influencing P and S, respectively (we also
assume that all variable specific error terms are uncorrelated).
Substituting equations (2) and (3) into equation (1), we obtain the re-
duced outcome model,
(4) Y = µ∗Y + β X + ψM + f
∗(U ,V ,H) + ǫ∗Y
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where β = η λ, ψ = φ τ+φ δ λ, µ∗Y = µY +λµS+(τ+δ λ)µP , ǫ
∗
Y = ǫY +λ ǫS+
(τ + δ λ) ǫP , and f
∗(U ,V ,H) = fY (U ,V ,H) + λ fS(H) + (τ + δ λ) fP (H).
Equation (4) represents the outcome model in Figure 1b.
Because the instrumental variable Q is randomized, and hence statistically
independent of any variables that are not directly or indirectly influenced
by Q, it follows from equation (4) and standard properties of the covariance
operator that,
Cov(Q,Y ) = Cov(Q,µ∗Y ) + β Cov(Q,X) + ψCov(Q,M)+(5)
+ Cov(Q, f∗(U ,V ,H)) + Cov(Q, ǫ∗Y )
= ψCov(Q,M) ,
since Q ⊥⊥ µ∗Y , Q ⊥⊥ X, Q ⊥⊥ f
∗(U ,V ,H), and Q ⊥⊥ ǫ∗Y , and the re-
spective covariance terms are 0 (here, the symbol ⊥⊥ stands for statistical
independence). Therefore, ψ can be identified as,
(6) ψ =
Cov(Q,Y )
Cov(Q,M)
,
as long as Cov(Q,M) 6= 0 (in practice, this condition is met if the psycho-
logical encouragement treatment can effectively manipulate the desire for
improved symptoms, which, by its turn influences the emotional state, M).
Now, if we let R = Y −ψM represent the residual of the outcome variable,
after removal of the placebo effect, then we can rewrite equation (4) as,
(7) R = µ∗Y + β X + f
∗(U ,V ,H) + ǫ∗Y .
Because Z is also randomized, it follows from equation (7) and the prop-
erties of the covariance operator that,
Cov(Z,R) = Cov(Z, µ∗Y ) + β Cov(Z,X)+(8)
+ Cov(Z, f∗(U ,V ,H)) + Cov(Z, ǫ∗Y )
= β Cov(Z,X) ,
since Z ⊥⊥ µ∗Y , Z ⊥⊥ f
∗(U ,V ,H), and Z ⊥⊥ ǫ∗Y . Hence, the treatment effect
β can be identified as,
(9) β =
Cov(Z,R)
Cov(Z,X)
,
as long as Cov(Z,X) 6= 0 (in practice, this condition is met whenever there
is some degree of compliance between assigned and received treatments).
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Note that in addition to the three core assumptions required by an IV[14]
(namely, that it is statistically independent of any unmeasured confounders;
is marginally associated with the treatment variable; and is associated with
the outcome variable exclusively through its influence on the treatment vari-
able), the above derivations require that X and M are linearly related to
Y , but make no assumptions about the relationship between Y and the un-
measured confounders. Estimators for the placebo and treatment effects in
equations (6) and (9) are presented in the next subsection.
An alternative statistical framework, based on Rubin’s potential outcomes
approach to causality[30, 31], has been proposed in the literature to address
partial compliance in studies involving binary instrumental and treatment
variables[32, 31]. While the method in reference[32] is not directly applicable
to the estimation of the placebo effects, it could be used to estimate treat-
ment effects (after removal of the placebo effect). We point out, however,
that the estimator obtained from the potential outcome approach is still
identical to the estimator derived from the mechanism based approach, so
that statistical inferences based on randomization tests are still the same,
independent of the causality framework one is willing to adopt.
5.2. Two-step estimation procedure. Adopting a method of moments ap-
proach, we have that a consistent estimator for ψ is given by,
(10) ψˆ =
Ĉov(Q,Y )
Ĉov(Q,M)
=
1
n
∑n
k=1QkYk − (
1
n
∑n
k=1Qk)(
1
n
∑n
k=1 Yk)
1
n
∑n
k=1QkMk − (
1
n
∑n
k=1Qk)(
1
n
∑n
k=1Mk)
.
Note that the above placebo effect estimator requires measurements of
M , but not of E or D. We point out, however, that if expectation and desire
measurements are also available, then we can evaluate the validity of the
desire-expectation model for the data at hand by checking whether the E,
D, and I variables are able to predict the M measurements. We can also
assess the effectiveness of the psychological treatment in influencing desire
for better symptoms by estimating Cor(Q,D).
Direct estimation of the treatment effect in equation (9) using an IV es-
timator is unfeasible, as it would involve the unmeasured quantities Rk =
Y −ψMk. Therefore, in order to obtain a consistent estimator of the treat-
ment effect, we adopt a two-step approach where we first estimate Rk as
R̂k = Yk − ψˆ Mk, for k = 1, . . . , n, and then estimate β using,
(11) βˆ =
Ĉov(Z, R̂)
Ĉov(Z,X)
=
1
n
∑n
k=1 ZkR̂k − (
1
n
∑n
k=1 Zk)(
1
n
∑n
k=1 R̂k)
1
n
∑n
k=1 ZkXk − (
1
n
∑n
k=1 Zk)(
1
n
∑n
k=1Xk)
.
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Note that the IV estimators in equations (10) and (11) can produce highly
inflated estimates when Ĉov(Q,M) ≈ 0 and Ĉov(Z,X) ≈ 0. Hence, in prac-
tice, it is important to check the assumptions that psychological encour-
agement influences the emotion levels, and that the compliance between
assigned and received treatments is not negligible.
5.3. Randomization tests for H0 : ψ = 0 and H0 : β = 0. We imple-
mented randomization tests[33] for testing the presence of a placebo effect
(H0 : ψ = 0 versus H1 : ψ 6= 0), and of a treatment effect (H0 : β = 0 versus
H1 : β 6= 0). The randomization null distribution for the placebo effect is
generated by evaluating the statistic ψˆ in equation (10) on a large number of
shuffled versions of the data, where the Yk measurements are shuffled relative
to the (Qk,Mk) measurements (whose connection is kept intact in order to
preserve the association between the Q and M variables). The randomiza-
tion null for treatment effect is generated by first calculating the residuals,
R̂k = Yk− ψˆ Mk, where ψˆ is computed in the observed (not permuted) data,
and then evaluating the statistic βˆ in equation (11) in shuffled data sets,
where Rk is shuffled relative to (Zk,Xk) data (whose connection is kept in-
tact to preserve the association between Z and X). These randomization
tests are non-parametric procedures and don’t make any distributional as-
sumptions about the data. However, because the identification of the causal
effects assumes a linear relation between Y and X and M , the validity of
the tests is still contingent on this assumption.
5.4. Randomization confidence intervals. Here we describe how to build
confidence intervals for placebo and treatment effects using the p-values from
randomization tests[34, 33]. Throughout this section we use θ to represent
either the placebo effect, ψ, or the treatment effect, β. The procedure is
strait-forward but requires a considerable amount of computation (which,
nonetheless, can be easily parallelized). Assume for a moment that random-
ization tests for testing H0 : θ = θj against one-sided alternative hypotheses
H1 : θ < θj and H1 : θ > θj are available. Exploring the correspondence
between confidence intervals and hypothesis tests, we obtain a 100(1−2α)%
confidence interval (CI) for θ by searching for a lower bound value, θL, such
that H0 : θ = θL is rejected in favor of H1 : θ > θL at a significance α, and
by searching for an upper bound value, θU , such that H0 : θ = θU is rejected
in favor of H1 : θ < θU at the same significance level[34].
While an efficient algorithm for finding CI bounds has been proposed[34],
the approach requires the specification of the significant level before hand.
In order to avoid this constraint, we generate a one-sided randomization p-
value profile which can be used to determine the 100(1 − 2α)% CI for any
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desired α level. This p-value profile is generated as follows: (i) compute the
observed placebo or treatment effect estimate, θˆ; (ii) for each θj < θˆ, in a
grid of decreasing θj values, compute the randomization p-value from the
one-sided test H0 : θ = θj vs H1 : θ > θj; (iii) repeat step ii until a p-value
equal to zero is reached; (iv) for each θj > θˆ, in a grid of increasing θj values,
compute the p-value from the one-sided test H0 : θ = θj vs H1 : θ < θj; (v)
repeat step iv until a randomization p-value equal to zero is found.
Before we explain how to generate null distributions for placebo effects
different from zero, consider first the intention-to-treat (ITT) estimator,
(12) ÎTTψ =
∑n
k=1 Yk 1 {Qk = 1}∑n
k=1 1 {Qk = 1}
−
∑n
k=1 Yk 1 {Qk = 0}∑n
k=1 1 {Qk = 0}
=
Ĉov(Q,Y )
V̂ar(Q)
.
Instead of directly generating a randomization distribution under the null
H0 : ψ = ψj , we generate a randomization distribution under the equivalent
null hypothesis that the intention-to-treat effect is equal to ψj K1, where
K1 = Ĉov(Q,M)/V̂ar(Q) is constant across all permutations of the response
data used in the construction of the randomization null. (Note that, because
ÎTTψ = K1 ψˆ the randomization tests based on ψˆ and ÎTTψ estimators
produce exactly the same p-value if we use the same permutations of the
response data in the construction of their null distributions.)
The practical advantage of the test based on ITTψ effects is that it
amounts to a simple two sample location problem for testing whether the
difference in average response between the assigned treatment (psychological
encouragement) and assigned control (no encouragement) groups is equal to
ψj K1. The implementation of randomization tests for this two sample lo-
cation problem is strait-forward[34]: we only need to add ψj K1 for each Yk
data point in the assigned control group (i.e., k for which Qk = 0), while
leaving the response data from the assigned treatment group, Qk = 1, un-
changed, and then run a randomization test for testing the null hypothesis
that the ITTψ effect is equal to zero, against the alternative one-sided hy-
pothesis that it is positive, and against the alternative that it is negative.
Similarly, for the treatment effects we consider the two-step ITT estima-
tor,
(13) ÎTT β =
∑n
k=1 Rˆk 1 {Zk = 1}∑n
k=1 1 {Zk = 1}
−
∑n
k=1 Rˆk 1 {Zk = 0}∑n
k=1 1 {Zk = 0}
=
Ĉov(Z, Rˆ)
V̂ar(Z)
,
and generate randomization distributions under the equivalent null hypothe-
ses H0 : ITTβ = βj K2, where K2 = Ĉov(Z,X)/V̂ar(Z), by simply adding
βj K2 for each Rˆk data point in the assigned control group, Zk = 0, while
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leaving the residual data from the assigned treatment group, Zk = 1, un-
changed (and then testing for the null that the ITTβ is equal to zero, against
the alternative one-sided hypotheses that it is positive and the alternative
that it is negative0.
5.5. Adjustment for observed confounders. If measured confounders in-
fluencing both X and Y are available, it is possible to adjust for them by
simply working with the residuals of X and Y (computed by separately re-
gressing X and Y on the confounders). Similarly, if measured confounders
influencing both M and Y are available, it is possible to adjust for them by
working with the respective residuals.
5.6. Regression based estimators and tests. We compare the proposed IV
estimators, and their respective randomization tests, to standard estimators
and analytical hypothesis tests based on the linear regression of the out-
come variable, Y , on both the received treatment, X, and emotion level, M ,
according to the model, Y = µY + β X + ψM + ǫY . Under this regression
based approach, we estimate β and ψ using ordinary least squares, and test
the null hypotheses H0 : ψ = 0 and H0 : β = 0 using standard t-tests. In
our simulations (described next), we generate data using gaussian errors,
so that the distributional assumptions underlying the analytical t-tests are
met.
5.7. Simulation experiments details. We simulated data from blinded
and unblinded settings, in the presence or absence of confounding, according
to the models presented in Figure 2. For each of these settings, we run 4
separate simulation studies generating data: (i) under the null hypothesis
that both treatment and placebo effect are zero, H0 : β = 0 and H0 : ψ = 0;
(ii) under the alternative for treatment effects, H1 : β 6= 0, but null for
placebo effects, H0 : ψ = 0; (iii) the other way around, H0 : β = 0 and
H1 : ψ 6= 0; and (iv) under the alternative for both treatment and placebo
effects, H1 : β 6= 0 and H1 : ψ 6= 0.
Each simulated data set was generated as follows. The IVs Z and Q were
sampled from Bernoulli(1/2) distributions. All confounding variables were
sampled from Normal(0, 1) distributions. The binary variables X, E, and D
were generated by the threshold models,
X = 1 {θXZ Z + θXU U + θXC1 C1 + θXC2 C2 + θXC3 C3 + ǫX > 0} ,(14)
E = 1 {θEX X + θEC1 C1 + θEL1 L1 + θEV2 V2 + θEL3 L3 + ǫE > 0} ,(15)
D = 1 {θDQQ+ θDV1 V1 + θDC2 C2 + θDL2 L2 + θDL3 L3 + ǫD > 0} ,(16)
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where ǫX , ǫE , and ǫD were sampled from Normal(0, 1) distributions. The
interaction I was generated as the product of E and D. Finally, the emotion
and outcome data were generated from the linear models,
(17)
M = θME E+θMDD+θMI I+θML1 L1+θML2 L2+θMC3 C3+θMV3 V3+ǫM ,
(18) Y = θY X X + θYM M + θY U U + θY V1 V1 + θY V2 V2 + θY V3 V3 + ǫY ,
where ǫM and ǫY were sampled from Normal(0, 1) distributions. (Note that
the explicit form of the desire-expectation model of emotions is unimportant,
as the estimator for ψ depends on the observed values of M , but not of E,
D, and I, and does not require an explicit description of the functional
relationships between M and E, D, and I. Hence, for simplicity, we adopt a
simple linear relation, even though more sophisticated relations could have
been used.)
Each simulation experiment comprised 10,000 distinct synthetic data sets.
Each simulated data set was generated using a unique combination of sim-
ulation parameter values. In order to select parameter values spread as uni-
formly as possible over the entire parameter range we employed a Latin hy-
percube design[35], optimized according to the maximin distance criterium
[36], in the determination of the parameter values used on each of the 10,000
simulated data sets for each simulation experiment.
We selected wide ranges for all model parameters. Explicitly, the pa-
rameters representing the effect of confounders on the observed variables
(namely, θXU , θXC1 , θXC2 , θXC3 , θEC1 , θEL1 , θEV2 , θEL3 , θDV1 , θDC2 , θDL2 ,
θDL3 , θML1 , θML2 , θMC3 , θMV3 , θY U , θY V1 , θY V2 , and θY V3) were selected in
the range [−2, 2] for the simulations under the influence of confounders, but
were set to 0 in the simulations under unconfounded conditions. The effect
of Z on X (θXZ), and of Q on D (θDQ), as well as, the effects of E, D, and I
onM (θME , θMD, and θMI) were selected in the range [1, 2]. The effect of X
on E (θEX) was set to 0 in the blinded setting simulations, and selected in
the range [1, 2] in the unblinded simulations. The treatment effect (β) and
the placebo effect (ψ) parameters were set to 0 in the simulations under the
null hypothesis, and were selected in the range [−2, 2] for the simulations
under the alternative hypothesis. The range of sample size parameter, n,
was set to realistic values we expect to see in practice, {100, 101, . . . , 1000}.
For any fixed significance level α, the empirical type I error rate was
computed as the fraction of the p-values smaller than α over the data sets
simulated under the null hypothesis, whereas the empirical power was cal-
culated as the fraction of p-value smaller than α over data sets generated
under the alternative hypothesis.
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